



- (51) **International Patent Classification:**
C07K 16/24 (2006.01) *A61P 11/00* (2006.01)
- (21) **International Application Number:**
PCT/US2025/010264
- (22) **International Filing Date:**
03 January 2025 (03.01.2025)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/618,273 05 January 2024 (05.01.2024) US
- (71) **Applicants:** **MEDIMMUNE, LLC** [US/US]; One MedImmune Way, Gaithersburg, MD 20878 (US). **AMGEN INC.** [US/US]; One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (US).
- (72) **Inventors:** **COLICE, Gene**; C/o MedImmune LLC, One MedImmune Way, Gaithersburg, MD 20878 (US). **PETERFFY, Annamaria, Jasmine**; C/o MedImmune LLC, One MedImmune Way, Gaithersburg, MD 20878 (US). **ALMQVIST, Gun, Inger**; C/o MedImmune LLC, One MedImmune Way, Gaithersburg, MD 20878 (US). **BOWEN, Karin, Rachel**; C/o MedImmune LLC,

One MedImmune Way, Gaithersburg, MD 20878 (US). **PARNES, Jane, R.**; C/o Amgen Inc., One Amgen Center Drive, Mail Stop 28-5-a, Thousand Oaks, CA 91320-1799 (US). **ABUQAYYAS, Lubna**; C/o Amgen Inc., One Amgen Center Drive, Mail Stop 28-5-a, Thousand Oaks, CA 91320-1799 (US). **COHEN, David**; C/o AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, DE 19850 (US).

- (74) **Agent:** **NEVILLE, Katherine, L.**; Marshall, Gerstein & Borun LLP, 233 S. Wacker Drive, 6300 Willis Tower, Chicago, IL 60606-6357 (US).

- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (54) **Title:** TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH ANTI-TSLP ANTIBODY

Figure 1

ICS component	Conversion Factor (i.e. multiply dose by X)	Minimum acceptable daily dose (mcg)
Fluticasone propionate	1	>250
Fluticasone propionate HFA	1.14	>220 (per actuation)
Fluticasone furoate	2.5	≥100 (metered) ≥92 (delivered)
Budesonide (metered/delivered dose)	0.63/0.78	>400 (metered) >320 (delivered)
Budesonide (nebulized)	0.5	>0.5 mg (2 ml ampules)
Beclomethasone	0.5	>500
Beclomethasone (Trinbow)	1.25	400 (metered) 348 (delivered dose)
Beclomethasone extra-fine particles and HFA (Fostair, QVAR)	1.04 (metered dose) 1.25 (dose per actuation)	>250 (metered dose) >200 (per actuation)
Ciclesonide	1.56	>160
Mometasone furoate	1.14	>220 (metered) >200 (per actuation)
Flunisolide	0.25	>1000
Triamcinolone	0.25	>1000

Source: GOLD 2018; GINA 2018

ICS component	Conversion Factor (i.e. multiply dose by X)	Minimum acceptable daily dose (mcg)
Budesonide (metered/delivered dose)	0.63/0.78	>400 (metered) >320 (delivered)

- (57) **Abstract:** The present disclosure, relates, in general, to methods of treating chronic obstructive pulmonary disease (COPD) using an antibody specific for thymic stromal lymphopoietin (TSLP).

[Continued on next page]



(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*